Amyloidosis Stocks List

Amyloidosis Stocks Recent News

Date Stock Title
May 17 IONS Ionis, Biogen Down on Ending Development of ALS Drug
May 17 ABUS Update: Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program
May 17 ABUS Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program
May 17 IONS Ionis (IONS), Biogen Down on Ending Development of ALS Drug
May 17 ABUS Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
May 16 IONS Biogen also drops collaboration with Ionis on Angelman syndrome candidate
May 16 IONS Biogen and Ionis drop ALS candidate after trial setback
May 16 IONS Biogen, Ionis shelve ALS drug following study failure
May 16 IONS REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug
May 16 IONS Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16 IONS Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16 IONS Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
May 15 GMAB Market Chatter: Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'
May 15 IONS Ionis to host 2024 virtual Annual Meeting of Stockholders
May 15 ABOS Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
May 15 ABOS Q1 2024 Acumen Pharmaceuticals Inc Earnings Call
May 14 ABOS Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript
May 14 GMAB Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
May 14 NTLA Intellia Therapeutics, Inc. (NTLA) Just Overtook the 50-Day Moving Average
May 14 ALZN Alzamend Neuro Announces Initial Closing of Private Placement
Amyloidosis

Amyloidosis is a disease in which abnormal proteins, known as amyloid fibrils, build up in tissue. There are several types with varying symptoms; signs and symptoms may include diarrhea, weight loss, feeling tired, enlargement of the tongue, bleeding, numbness, feeling faint with standing, swelling of the legs, or enlargement of the spleen.There are about 30 different types of amyloidosis, each due to a specific protein misfolding. Some are genetic while others are acquired. They are grouped into localized forms, and systemic ones. The four most common types of systemic amyloidosis are light chain (AL), inflammation (AA), dialysis-related (Aβ2M), and hereditary and old age (ATTR and familial amyloid polyneuropathy).Diagnosis may be suspected when protein is found in the urine, organ enlargement is present, or problems are found with multiple peripheral nerves and it is unclear why. Diagnosis is confirmed by tissue biopsy. Due to the variable presentation, a diagnosis can often take some time to reach.Treatment is geared towards decreasing the amount of the involved protein. This may sometimes be achieved by determining and treating the underlying cause. AL amyloidosis occurs in about 3–13 per million people per year and AA amyloidosis in about 2 per million people per year. The usual age of onset of these two types is 55 to 60 years old. Without treatment, life expectancy is between six months and four years. In the developed world about 1 per 1,000 people die from amyloidosis. Amyloidosis has been described since at least 1639.

Browse All Tags